LIVE

CBT

Cabot Corp.

CBT

NYSE·Basic Materials·Chemicals - Specialty·Mkt cap $4.5B

$86.35

▼ -0.40%

View full research view

Our plain-language verdict, the thesis, risk factors, and what is changing about the business.

View research view

52-Week Range

$58.33 - $94.53

P/E

15.10

Fwd P/E

13.67

Beta

0.83

Div Yield

2.10%

Avg Vol

495.1K

Shares Out

52.2M

Mkt Cap

$4.5B

Price action

Price chart

Up 9.8% over the trailing year

1W
1M
3M
6M
YTD
1Y
5Y
MAX

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

▲

Bull Case

5 reasons

  • 140+ year heritage and deep expertise in carbon chemistry and materials science
  • Diversified product portfolio serving multiple high-demand industries and end-markets
  • Global distribution network with established relationships across Americas, Europe, EMEA, and Asia Pacific
  • Proprietary manufacturing processes and technical capabilities in specialty materials
  • Strong customer base including major automotive, tire, and industrial manufacturers
▼

Bear Case

1 risk

  • Average volatility.

Growth

Stable outlook

Rising demand for high-performance materials in electric vehicle batteries and energy storage

Value

Attractively priced below Specialty Chemicals peer average

Momentum

Strong

+14.2% over 3m

Quality

Stable

Strong fundamentals

Dividend

Solid

2.10% yield

Earnings track record

Latest print - beat on both lines

AI-summarized recap of last quarter, plus the surprise on every print.

Next: May 4, 2026

“
Q2 26 RECAP

MAY 5, 2026

Reported EPS of $1.61 vs $1.47 consensus (+9.5% surprise). Revenue of $904.0M vs $900.3M expected (+0.4%). Beat on both top and bottom lines.

EPS beat +9.5%
Rev beat +0.4%
Double beat

EPS surprise · last 4Q

1 of 1 beats

Q2 26

+9.5%

Next: May 4, 2026

Revenue trend · last 8Q

—

—

—

-0%

-8%

-9%

-10%

-11%

Q2 24

Q3 24

Q4 24

Q1 24

Q2 25

Q3 25

Q4 25

Q1 25

$1.0B

$1.0B

$1.0B

$955.0M

$936.0M

$923.0M

$899.0M

$849.0M

Margins · last 8Q

Gross

24.9%

Operating

15.2%

Profit

8.6%

View full earnings history →

Wall Street consensus

3 analysts · 0% Buy

Live ratings and price targets aggregated across covering analysts.

Buy

0%

Hold

2

67%

Sell

1

33%

Median Price Target

$86.00

▼ -0.4% vs $86.35

Low $86.00
Median $86.00
High $86.00

Latest: JP Morgan · May 13, 2026

1 analyst covering

View full analyst page →

vs Industry

How CBT stacks vs Chemicals - Specialty

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.